Loading...
  • immune responses
  • In particular, in the elimination phase, cells of the innate and adaptive immune responses may eradicate the developing tumor and protect the host from tumor formation. (asm.org)
  • ref. 22 ) can alter the immunosuppressive milieu and aid in the initiation of antigen-specific immune responses ( 17 , 18 ). (aacrjournals.org)
  • However, recent findings suggest that combination of reovirus-mediated oncolysis and host immune responses is necessary to achieve efficient tumor regression associated with this virotherapy ( 29 ). (aacrjournals.org)
  • We show that therapeutic administration of reovirus overrides tumor-associated antigen presentation abnormalities before initiating tumor-specific adaptive immune responses. (aacrjournals.org)
  • Immune responses targeting these proteins could thus result in a limited or no generation of antigen-loss variants and, therefore, they may efficiently control in vivo tumor growth, thus meeting the requirements for an ideal TAA set forth above. (aacrjournals.org)
  • The paradoxical coexistence of spontaneous tumor antigen-specific immune responses with progressive disease in cancer patients furthers the need to dissect the molecular pathways involved in tumor-induced T cell dysfunction. (nih.gov)
  • The gp75 antigen presented by HLA-A31 may therefore constitute a useful immune target for specific treatment of patients with melanoma, since both antibody- and T cell-mediated immune responses can be generated against this antigen. (rupress.org)
  • antibody
  • Consistent with this train of thought, the targets of approved antibody therapies are predominantly extracellular antigens ( 1 ). (frontiersin.org)
  • elicit
  • Induction of T cell tolerance suggests tumor antigen-T cell interactions occurring during tumorigenesis may elicit T cell tolerance and hence confound some immunotherapeutic approaches. (wiley.com)
  • molecule
  • Traditionally, immune checkpoint molecule is not included in the tumor antigens. (hstalks.com)
  • In the presence of the relevant antigen-positive cell line, each respective DART molecule was able to promote T-cell proliferation and cytokine release in a HER2 or EphA2-dependent manner. (aacrjournals.org)
  • The present and previous studies indicated that TIL586 recognized an antigen expressed on most melanoma and normal melanocytes in the context of the HLA-A31 molecule. (rupress.org)
  • molecules
  • By contrast, small molecules have been used to target those intracellular antigens with a functionality that is suitable for drug screening. (frontiersin.org)
  • Co-culturing of a CD137/NF-κB reporter cell line with tumor lines expressing HER2 or EphA2 revealed tumor antigen-dependent CD137 pathway activation by HER2 x CD137 and EphA2 x CD137 DART molecules, respectively. (aacrjournals.org)
  • stimulation
  • Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. (rcsb.org)
  • expression
  • Spas-1 expression was increased in advanced primary TRAMP tumors. (nih.gov)
  • Spas-1 expression is not restricted to the prostate but is increased in older TRAMP tumors. (nih.gov)
  • The clinical potential of these antigens is hampered by their limited expression in ALL patients or by their restricted presentation by nonprevalent HLA alleles. (aacrjournals.org)
  • identification
  • This review will summarize multiple approaches to targeting intracellular antigens with therapeutic antibodies, in particular describing the production and characterization of TCRm antibodies, the factors influencing their target identification, their advantages and disadvantages in the context of TCR therapies, and the potential to advance TCRm-based therapies into the clinic. (frontiersin.org)
  • antitumor
  • However, while vaccines have proven to be effective in combating pathogenic microorganisms, based on the immune recognition of these foreign antigens, vaccines aimed at inducing effective antitumor activity are still unsatisfactory. (asm.org)
  • Tumors use various evasion strategies to inhibit the development of antitumor immunity and avoid subsequent immune response-mediated elimination ( 1 - 3 ). (aacrjournals.org)
  • Additionally, reovirus oncotherapy synergistically enhances the efficacy of tumor-specific immunotherapies and, most importantly, promotes the establishment of protective antitumor immunity. (aacrjournals.org)
  • Clinical
  • Unique TAAs are now being frequently found in several human tumors, although their use in clinical trials is difficult for the time required to characterize unique TAAs at a single patient level ( 8 , 9 , 13 ). (aacrjournals.org)
  • novel
  • AbbVie leverages its expertise across multiple technology platforms to identify novel antigens and approaches needed to target them. (abbvie.com)